Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis

Journal of Medical Virology

Volumn 88, Issue 9, 2016, Pages 1576-1586

  An, Jihyun ^a   Shim, Ju Hyun ^a   Kim, Seon Ok ^a   Choi, Jonggi ^a   Kim, Sang We ^a   Lee, Danbi ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Vievisnamuh Hospital   (South Korea)

Author keywords

antiviral prophylaxis; cancer; chemotherapy; hepatitis B virus; reactivation; relapse

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; CORTICOSTEROID; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RITUXIMAB; TELBIVUDINE; TENOFOVIR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HEPATITIS B; HODGKIN DISEASE; HUMAN; INCIDENCE; INFECTION PREVENTION; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD; VIRUS REACTIVATION;

EID: 84977670320     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24512     Document Type: Article

References (31)

1. Alter MJ. 2003. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39:S64–S69.
2. Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM. 2014. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 61:515–522.
3. Chen FW, Coyle L, Jones BE, Pattullo V. 2013. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int 33:1203–1210.
4. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. 2015. Recent US food and drug administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg? Hepatology 61:703–711.
5. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. 2013. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis. J Clin Virol 57:209–214.
6. European Association for the Study of the Liver Diseases. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167–185.
7. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. 2011. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170–1180.
8. Fine JP, Gray RJ. 1999. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509.
9. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T. 2014. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. JAMA 312:2521–2530.
10. Hui CK, Cheung WWW, Au WY, Lie AK, Zhang HY, Yueng YH, Wong BCY, Leung N, Kwong YL, Liang R, Lau GKK. 2005. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54:1597–1603.
11. Hwang JP, Barbo AG, Perrillo RP. 2015. Hepatitis B reactivation during cancer chemotherapy: An international survey of the membership of the american association for the study of liver diseases. J Viral Hepat 22:346–352.
12. Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. 2013. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 58:1888–1896.
13. Korean Association for the Study of the Liver Diseases. 2012. KASL clinical practice guidelines: Management of chronic hepatitis B. Clin Mol Hepatol 18:109–162.
14. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R. 2002. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99:2324–2330.
15. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim do Y, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. 2010. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis. B Hepatology 51:415–421.
16. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC, Lin TY. 2011. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 18:877–883.
17. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ. 2006. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106:1320–1325.
18. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. 1991. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188.
19. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: Update 2009. Hepatology 50:661–662.
20. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. 2008. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528.
21. Ludwig E. 2014. HBV reactivation in immunosuppressed patients: Prevention or containment? Hepatology 59:2062–2064.
22. Mindikoglu AL, Regev A, Schiff ER. 2006. Hepatitis B virus reactivation after cytotoxic chemotherapy: The disease and its prevention. Clin Gastroenterol Hepatol 4:1076–1081.
23. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. 2010. Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255–262.
24. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. 2015. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215–219; quiz e216–217.
25. Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL. 2015. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: A multicentre prospective study. Gut 64:667–672.
26. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. 2000. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307.
27. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ. 2004a. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927–934.
28. Yeo W, Zee B, Zhong S, Chan PKS, Wong WL, Ho WM, Lam KC, Johnson PJ. 2004b. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311.
29. Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, Mok TS, Lee JJ, Mo FK, Johnson PJ. 2005. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 28:379–384.
30. Yeo W, Chan TC, Leung NWY, Lam WY, Mo FKF, Chu MT, Chan HLY, Hui EP, Lei KIK, Mok TSK, Chan PKS. 2009. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605–611.
31. Zhong S, Yeo W, Schroder C, Chan PK, Wong WL, Ho WM, Mo F, Zee B, Johnson PJ. 2004. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 11:55–59.